Inoue T, Doi S, Takamatsu I, Murayama N, Kameda M, Hayashida M, Nishida M, Toyoshima K
Department of Pediatric Allergy, Osaka Prefectural Habikino Hospital.
Arerugi. 1995 Jul;44(7):678-84.
To evaluate the influences of inhaled beclomethasone dipropionate (BDP), 7.3-30.9 (15.5 +/- 6.5) micrograms/kg/day, on bone metabolism and height growth, we performed a longitudinal study for 6 months in 34 children with asthma aged between 3 and 15 years. Bone mineral density estimated by digital image processing method (DIP) and serum level of osteocalcin did not show any significant change, but height growth was slightly suppressed in the patients who inhaled more than 15 micrograms/kg/day of BDP. We concluded that the decision to prescribe inhaled BDP should be made on the balance of the clinical effects and the improvement of quality of life against the possibility of side effects.
为评估吸入丙酸倍氯米松（BDP），剂量为7.3 - 30.9（15.5±6.5）微克/千克/天，对骨代谢和身高增长的影响，我们对34名3至15岁的哮喘儿童进行了为期6个月的纵向研究。通过数字图像处理方法（DIP）估算的骨密度和血清骨钙素水平未显示出任何显著变化，但吸入BDP超过15微克/千克/天的患者身高增长略有抑制。我们得出结论，开具吸入BDP的决定应基于临床效果和生活质量改善与副作用可能性之间的权衡。
